IP Library Granted Patent US 10,952,977
Granted Patent B2
US 10,952,977 · App. 16/208,394 · Granted Mar 23, 2021

Hydroxy-substituted amino and ammonium derivatives and their medical use

Inventors: Georg Schlechtingen (Dresden, DE); Hans-Joachim Knolker (Dresden, DE); Tim Friedrichson (Dresden, DE); Gary Jennings (Dresden, DE); Tobias Braxmeier (Kuppenheim, DE)
Assignee: GRI BIO, INC.
A61K31/164A61K45/06C07C237/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,952,977
App. No.
16/208,394
Granted
Mar 23, 2021
Kind
B2
Abstract

The present invention relates to hydroxy-substituted amino and ammonium derivatives, in particular the compounds of formula (1) or (2), and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder, or a proliferative, neoplastic or dysplastic disease or disorder.

Claims (13)

1. A method of inhibiting mast cell degranulation, Akt kinase, delayed-type hypersensitivity, allergic contact dermatitis inflammatory response, or collagen type II-induced arthritis, the method comprising administering an effective amount to a subject in need of such a treatment, a compound of the following formula 1

wherein:

R 1 is a C 10-20 hydrocarbon group;

R 2 is a C 1-4 alkyl group, and R 3 is —H, a C 1-4 alkyl group or R 3 is absent; or

R 2 and R 3 are mutually linked to form a pyrrolidine ring, a piperidine ring or an azepane ring together with the nitrogen atom X to which they are attached, wherein said pyrrolidine ring, said piperidine ring or said azepane ring is optionally substituted with one or more groups independently selected from —OH, —O(C 1-3 alkyl), —O—C(O)—(C 1-3 alkyl), C 1-3 alkyl, —NH 2 , —NH(C 1-3 alkyl) or —N(C 1-3 alkyl)(C 1-3 alkyl);

R 4 is —H or a C 1-4 alkyl group;

R 5 is a C 2-8 alkyl group, wherein one or more hydrogen atoms of said C 2-8 alkyl group are replaced by —OH, or R 5 is a C 5-7 cycloalkyl group, wherein one ring carbon atom of said C 5-7 cycloalkyl group is optionally replaced by an oxygen atom and wherein one or more hydrogen atoms of said C 5-7 cycloalkyl group are independently replaced by —OH or —CH 2 OH;

X is N + or, if R 3 is absent, X is N; and

p is 1, 2 or 3;

or a pharmaceutically acceptable salt, or solvate thereof.

2. The method of claim 1 , wherein said compound is administered by any one of: an oral route, topical route, transdermal or intravenous injection.

3. The method of claim 1 , wherein said subject is a human.

4. The method of claim 1 , wherein said subject is a nonhuman mammal.

Assignments (3)
SECURITY INTEREST Recorded Dec 15, 2022
From: GRI BIO, INC.
To: ALTIUM GROWTH FUND, LP
Reel/Frame 062108/0599 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2020
From: SCHLECHTINGEN, GEORG; KNOLKER, HANS-JOACHIM; FRIEDRICHSON, TIM; JENNINGS, GARY; BRAXMEIER, TOBIAS
To: GLYCOREGIMMUNE, INC.
Reel/Frame 054714/0417 →
CHANGE OF NAME Recorded Dec 21, 2020
From: GLYCOREGIMMUNE, INC.
To: GRI BIO, INC.
Reel/Frame 054822/0402 →
Priority Claims (1)
EP 1167741 · May 26, 2011 · regional
Continuity (3)
Division 15436678 · Feb 17, 2017
Division 14403166
Related Publication 20190175529A1 · Jun 13, 2019
Cited By (1)
US 12,528,775